The trial is testing whether using a generic drug to temporarily elevate tumor necrosis factor-alpha (TNF-a) levels in the body will reduce or eliminate autoimmune T cells in patients with established type 1 diabetes, an approach based on the Faustman lab’s previous success in reversing end-stage diabetes in mice. To learn more, please visit www.faustmanlab.org www.faustmanlab.org

Additional Links of Interest

Listen as Dr. Faustman describes her own research in "EFTR: Targeting Diabetes with an Old TB Vaccine"